Mereo Competitors

Stocks . USA . 
Stock . Mereo BioPharma Group
MREO Stock  USD 3.68  0.10  2.79%   
Mereo BioPharma Group competes with Terns Pharmaceuticals, PDS Biotechnology, Inozyme Pharma, Hookipa Pharma, and Day One; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Mereo BioPharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Mereo BioPharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Mereo BioPharma Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Mereo BioPharma competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mereo BioPharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.263.687.10
Details
Intrinsic
Valuation
LowRealHigh
0.163.236.65
Details

Mereo BioPharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mereo BioPharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Mereo and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mereo BioPharma Group does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
XFOR
+ 0.86
HOOK
HOOK
+ 0.74
INZY
INZY
+ 0.72
TERN
XFOR
+ 0.71
TERN
XFOR
+ 0.7
INZY
ABOS
+ 0.65
DAWN
  
High negative correlations   
AMLX
- 0.72
INZY
AMLX
- 0.61
HOOK
AMLX
- 0.61
TERN
AMLX
- 0.56
XFOR
ELEV
- 0.25
AMLX
ABOS
- 0.22
TERN

Risk-Adjusted Indicators

There is a big difference between Mereo Stock performing well and Mereo BioPharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mereo BioPharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
TERN  3.35 (0.50) 0.00 (0.32) 0.00 
 0.00 
 5.68 
(5.96)
 34.09 
PDSB  3.27 (0.45) 0.00  3.01  0.00 
 0.00 
 7.67 
(6.76)
 31.83 
INZY  2.67 (1.11) 0.00 (0.48) 0.00 
 0.00 
 5.68 
(7.92)
 16.62 
HOOK  2.69 (1.28) 0.00 (56.59) 0.00 
 0.00 
 4.05 
(7.24)
 22.98 
DAWN  2.12 (0.16) 0.00 (0.08) 0.00 
 0.00 
 3.84 
(3.69)
 11.44 
XFOR  4.94 (0.66) 0.00 (0.28) 0.00 
 0.00 
 6.90 
(10.61)
 62.35 
ABOS  3.52 (0.51) 0.00 (0.07) 0.00 
 0.00 
 7.52 
(6.67)
 28.07 
AMLX  4.28  1.29  0.27  1.16  4.03 
(5.02)
 10.06 
(6.13)
 33.56 
EFTR  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
ELEV  3.54 (0.35) 0.00 (0.71) 0.00 
 0.00 
 5.77 
(8.22)
 22.21 
All Fundamental Data

Mereo BioPharma Competitive Analysis

The better you understand Mereo BioPharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mereo BioPharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mereo BioPharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MREO TERN PDSB INZY HOOK DAWN XFOR ABOS AMLX EFTR
 2.79 
 3.68 
Mereo
 1.96 
 5.71 
Terns
 8.37 
 2.20 
PDS
 3.58 
 2.69 
Inozyme
 15.44 
 2.30 
Hookipa
 2.06 
 13.34 
Day
 8.82 
 0.37 
XFOR
 2.53 
 2.31 
Acumen
 0.76 
 5.19 
Amylyx
 30.00 
 0.13 
Effector
Market Volatility
(90 Days Market Risk)
Unstable
Relatively risky
Very risky
Slightly risky
Very risky
Not too volatile
Out of control
Very risky
Unstable
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Solid
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Average
Above Average
Average
Quite High
Average
Very High
Average
Low
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Strong Buy
Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Hold
Not Rated
Current Ratio
7.92
23.59
12.34
14.54
5.48
31.45
2.39
37.21
7.96
1.79
Net Asset
66.5 M
268.52 M
59.39 M
200.85 M
161.34 M
376.05 M
147.26 M
310.12 M
517.45 M
20.54 M
Profit Margin
N/A
N/A
N/A
N/A
-0.93
-0.83
31.32
N/A
-1.32
N/A
EBITDA
(26.06 M)
(102.27 M)
(40.08 M)
(74.81 M)
(77.34 M)
(206.06 M)
(107.1 M)
(51.61 M)
39.89 M
(33.73 M)
Operating Margin
-37.9
N/A
N/A
N/A
-17.37
0.32
-60.21
N/A
-181.88
N/A
Current Valuation
481.58 M
113.53 M
50.67 M
87.99 M
(24.14 M)
789.52 M
1.28 M
(33.09 M)
123.94 M
(4.52 M)
Price To Book
7.66
1.33
3.44
2.09
0.46
2.42
0.97
0.64
1.81
13.38
Retained Earnings
(419.63 M)
(332.63 M)
(144.5 M)
(285.93 M)
(369.26 M)
(458.58 M)
(477.9 M)
(222.8 M)
(304.95 M)
(179.38 M)
Current Asset
94 K
N/A
39.11 M
N/A
26.61 M
N/A
N/A
N/A
N/A
N/A
Beta
0.97
-0.33
1.93
1.54
0.83
-1.52
0.39
0.039
-0.7
0.83
Number Of Employees
33
66
25
59
151
174
127
51
384
14
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
50.03
N/A
Shares Outstanding
153.85 M
84.94 M
37.41 M
64.24 M
9.66 M
100.85 M
170.55 M
60.08 M
68.55 M
4.7 M
Cash Flow From Operations
(21.13 M)
(67.39 M)
(33.64 M)
(70.67 M)
(57.52 M)
(146.85 M)
(96.51 M)
(43.06 M)
11.92 M
(29.55 M)
Total Debt
5.95 M
603 K
23.85 M
46.59 M
6.56 M
408 K
58.28 M
28.49 M
4.24 M
19.45 M
Return On Equity
-0.48
-0.28
-1.28
-0.79
-0.49
-0.18
0.22
-0.33
-0.84
-9.47
Return On Asset
-0.24
-0.19
-0.4
-0.36
-0.2
-0.25
-0.4
-0.21
-0.43
-0.83
Number Of Shares Shorted
4.57 M
4.54 M
4.47 M
3.23 M
36.24 K
18.02 M
11.42 M
1.45 M
1.29 M
91.62 K
Book Value Per Share
0.51
4.29
0.79
1.29
7.45
5.51
0.31
3.62
2.86
0.21
Current Liabilities
729 K
N/A
4.54 M
N/A
25.01 M
N/A
N/A
N/A
N/A
N/A
Total Asset
66.5 M
268.52 M
59.39 M
200.85 M
161.34 M
376.05 M
147.26 M
310.12 M
517.45 M
20.54 M
Debt To Equity
0.19
0.01
0.007
0.02
0.052
0.002
1.28
N/A
0.036
1.03
Short Ratio
6.58
3.4
10.47
14.61
1.08
15.57
8.64
7.19
0.81
0.97
Target Price
7.22
18.19
11.9
18.75
43.0
37.0
2.68
10.8
7.5
11.0
Shares Owned By Institutions
65.66
97.72
12.35
96.67
37.16
93.1
67.66
78.48
82.46
23.71
Market Capitalization
630.8 M
485 M
75.75 M
172.81 M
32.79 M
1.35 B
62.76 M
138.78 M
355.76 M
846.79 K
Price To Earning
6.73
N/A
24.7
N/A
12.06
3.88
N/A
N/A
N/A
1.03
Price To Earnings To Growth
N/A
N/A
-0.05
-0.06
-0.19
N/A
N/A
-0.23
-0.15
N/A
Price To Sales
555.42
302.64
N/A
N/A
0.63
13.2
111.48
538.78
1.81
69.65
Net Income
(29.47 M)
(90.21 M)
(42.94 M)
(71.17 M)
(81.58 M)
(188.92 M)
(101.17 M)
(52.37 M)
49.27 M
(35.81 M)
Earnings Per Share
-0.25
-1.18
-1.17
-1.55
-3.67
-0.97
-0.07
-1.38
-3.82
-12.57
Shares Owned By Insiders
1.02
0.13
3.99
0.5
21.44
17.01
1.14
11.23
14.32
2.9
Revenue
10 M
N/A
N/A
N/A
20.13 M
N/A
N/A
N/A
380.79 M
N/A
Working Capital
54.27 M
255.49 M
45.43 M
181.56 M
105.13 M
345.77 M
99.21 M
233.64 M
382.62 M
(5.96 M)
Cash And Equivalents
94.3 M
139.81 M
52.98 M
151.48 M
117.92 M
394.86 M
47.38 M
189.91 M
206.68 M
41.04 M
Cash Per Share
0.81
5.51
1.86
3.77
2.16
5.38
0.69
4.69
3.53
0.99
Gross Profit
936 K
1000 K
N/A
N/A
(52.97 M)
N/A
3 M
(32.36 M)
(74.21 M)
(19.76 M)
Day Typical Price
3.61
5.65
2.14
2.7
2.41
13.45
0.36
2.32
5.2
0.12
Accumulation Distribution
0.065
0.057
0.0818
0.0679
0.2
0.0292
0.11
0.0625
0.0812
0.59
Market Facilitation Index
0.24
0.33
0.18
0.19
0.56
0.4
0.04
0.15
0.44
0.1
Daily Balance Of Power
0.4167
0.3333
0.9444
(0.53)
(0.75)
(0.70)
0.75
(0.40)
(0.09)
0.3
Period Momentum Indicator
0.1
0.11
0.17
(0.10)
(0.42)
(0.28)
0.03
(0.06)
(0.04)
0.03
Rate Of Daily Change
1.03
1.02
1.08
0.96
0.85
0.98
1.09
0.97
0.99
1.3
Day Median Price
3.57
5.63
2.11
2.71
2.47
13.5
0.35
2.33
5.2
0.12
Price Action Indicator
0.16
0.14
0.18
(0.07)
(0.38)
(0.30)
0.035
(0.04)
(0.03)
0.025
Relative Strength Index
40.85
38.98
35.47
23.05
21.53
43.66
39.8
42.14
56.32
18.1
Coefficient Of Variation
(904.29)
(1,366)
(1,062)
(389.80)
(293.67)
(4,053)
(2,067)
(2,264)
393.29
N/A
Mean Deviation
2.59
3.35
3.27
2.67
2.69
2.12
4.94
3.52
4.28
N/A
Jensen Alpha
(0.38)
(0.50)
(0.45)
(1.11)
(1.28)
(0.16)
(0.66)
(0.51)
1.29
N/A
Total Risk Alpha
(0.83)
(1.03)
(1.10)
(1.38)
(1.76)
(0.40)
(1.79)
(0.83)
0.68
N/A
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.271
N/A
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
23.26
N/A
Standard Deviation
3.42
5.03
4.85
3.55
3.71
2.54
9.95
4.69
5.57
N/A
Kurtosis
1.32
7.94
3.43
0.4506
2.92
(0.47)
18.75
1.77
1.99
N/A
Potential Upside
4.8
5.68
7.67
5.68
4.05
3.84
6.9
7.52
10.06
N/A
Treynor Ratio
4.65
(0.32)
3.01
(0.48)
(56.59)
(0.08)
(0.28)
(0.07)
1.16
N/A
Maximum Drawdown
17.36
34.09
31.83
16.62
22.98
11.44
62.35
28.07
33.56
N/A
Variance
11.69
25.33
23.48
12.6
13.76
6.45
98.99
22.03
31.04
N/A
Market Risk Adjusted Performance
4.66
(0.31)
3.02
(0.47)
(56.58)
(0.07)
(0.27)
(0.06)
1.17
N/A
Risk Adjusted Performance
(0.08)
(0.05)
(0.06)
(0.19)
(0.25)
(0.01)
(0.03)
(0.03)
0.2026
N/A
Skewness
(0.66)
1.99
(0.21)
0.1091
(0.63)
(0.31)
(0.68)
(0.36)
0.4927
N/A
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.03
N/A
Information Ratio
(0.14)
(0.09)
(0.12)
(0.29)
(0.37)
(0.07)
(0.06)
(0.07)
0.2346
N/A
Value At Risk
(5.79)
(5.96)
(6.76)
(7.92)
(7.24)
(3.69)
(10.61)
(6.67)
(6.13)
N/A
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(5.02)
N/A
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
4.82
N/A
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
16.27
N/A

Mereo BioPharma Competition Performance Charts

Five steps to successful analysis of Mereo BioPharma Competition

Mereo BioPharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mereo BioPharma Group in relation to its competition. Mereo BioPharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Mereo BioPharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mereo BioPharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mereo BioPharma Group, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Mereo BioPharma position

In addition to having Mereo BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Copper Thematic Idea Now

Copper
Copper Theme
Companies involved in production of copper. The Copper theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:
How To Invest In Mereo
Details
Is Mereo Stock a good investment?
Details
What is Mereo BioPharma's Net Worth?
Details
Largest Pharmaceutical Products Companies
View
Largest Biotechnology Companies
View
Check out Mereo BioPharma Correlation with its peers.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY